A new daily pill, Enlicitide, developed by Merck, has shown promising results in reducing "bad" LDL cholesterol levels by 60%, according to a recent study published in the Journal of the American Medical Association (JAMA). The trial, led by Dr. Christie M. Ballantyne of the Texas Heart Institute, involved 303 adults with heterozygous familial hypercholesterolemia (HeFH) across 59 medical sites in 17 countries.

Participants, who were already on lipid-lowering therapies, were randomly assigned to receive either 20 mg of Enlicitide or a placebo daily for 52 weeks. By week 24, those taking Enlicitide experienced an average LDL reduction of 58% , while the placebo group saw almost no change. The effect remained consistent through the one-year mark, with the Enlicitide group maintaining

See Full Page